Glucagon-Like-Peptide-1 receptor agonists (GLP-1 RA) are a class of medications originally developed to treat type 2 diabetes, but have since gained widespread attention for their effects on weight loss and metabolic health. Emerging research suggests that GLP1-Receptor Agonists could be supportive in managing inflammatory symptoms associated with Mast Cell Activation Syndrome (MCAS). Although research is currently limited, Anna talks about what we know so far and her experience with clients taking these drugs in clinical practice.
Useful Links
Research Paper: https://www.sciencedirect.com/science/article/abs/pii/S0002962925011061
Take the Chronic Fatigue Quiz: https://app.annamarsh.co.uk/quiz-page
Instagram: https://www.instagram.com/anna__marsh_
Work with me: https://annamarsh.co.uk/work-together/
Website: http://annamarsh.co.uk/
Join the Nurturing Resilience Subscription: https://annamarsh.co.uk/nurturing-resilience/
Contrary to what many people think about Chronic Fatigue Recovery, we are not supposed to be calm all the time. Rest matters and we...
Not all post-exertional malaise (PEM) is driven by the same physiology — and understanding the difference can completely change how you approach pacing and...
Shownotes Anna discusses the link between fatigue, mood disorders and chronic pain. Although these conditions are often not well supported with traditional medicine, they...